Continuous Glucose Monitoring Report
: Analysis on the Market, Trends, and TechnologiesThe continuous glucose monitoring market shows a rapid commercial and technological expansion with an addressable market size of US $12,400,000,000 and a forecasted climb to US $47,100,000,000, driven by a 16% CAGR in core projections. This growth rests on three linked forces: widening clinical coverage (including over-the-counter access), sensor life and comfort improvements that lower user friction, and the emergence of predictive analytics that move CGM from passive measurement toward proactive glycemic management grandviewresearch – Continuous Glucose Monitoring Devices Market Report
We updated this report 69 days ago. Noticed something’s off? Let’s make it right together — reach out!
Topic Dominance Index of Continuous Glucose Monitoring
The Topic Dominance Index trendline combines the share of voice distributions of Continuous Glucose Monitoring from 3 data sources: published articles, founded companies, and global search
Key Activities and Applications
- Real-time glucose tracking for insulin-treated patients — Continuous monitoring remains core for Type 1 and insulin-dependent Type 2 patients; sensors and receiver stacks deliver minute-by-minute streams that materially reduce hypoglycemia and improve Time-In-Range metrics
- Automated insulin delivery (AID) and closed-loop systems — CGM feeds algorithmic controllers that adjust basal rates and bolus timing, creating stepped improvements in HbA1c and hypoglycemia avoidance versus CGM alone U.S. Continuous Glucose Monitoring Systems (CGMS) Market.
- Remote patient monitoring and telehealth integration — Home-use CGMs that stream to clinicians enable population management and reduce clinic visits while enabling faster medication adjustments
- Metabolic health, prevention, and wellness use cases — CGM is moving beyond diagnosed diabetes into prediabetes, weight-management cohorts, and performance nutrition where real-time glycemic response informs behavioral coaching and DTx models finance.yahoo - Continuous Glucose Monitoring Devices Market Report.
- Specialized clinical deployments — ICU, perioperative, and post-bariatric management use CGM to track glycemic variability in contexts where fingerstick frequency is impractical
Emergent Trends and Core Insights
- Non-invasive sensing is accelerating as a strategic priority. Multiple physics-based approaches — Raman spectroscopy, photoacoustics, breath and thermal sensing, magnetohydrodynamics — are now in advanced R&D and early commercialization efforts, aiming to remove the needle barrier that limits adoption.
- Sensor longevity and implantables scale clinical convenience. Longer-wear sensors and implantable fluorescence platforms extend wear from days to months, shifting economics away from frequent consumable replacement and toward multi-year device strategies
- Predictive analytics and AI capture investor attention. Funding and product roadmaps increasingly prioritize models that forecast glucose excursions 30–120 minutes ahead and recommend or actuate interventions, which raises the value of software-first players relative to hardware-only vendors Continuous Glucose Monitoring Dominates Diabetes Management.
- Market bifurcation: sensor incumbents vs. insurgent non-invasive players. Large device manufacturers retain dominant share in sensors and durables, while numerous smaller teams pursue non-invasive and multi-analyte concepts that could redefine addressable markets if clinical accuracy and regulatory approvals are achieved.
- Accessibility and cost pressure create strategic openings in emerging markets. Low-cost, locally manufactured CGMs and simplified reimbursement approaches represent the clearest path to unlock high-volume growth outside North America and parts of Europe.
Technologies and Methodologies
- Electrochemical enzyme sensors (interstitial fluid) — The prevailing architecture for accurate clinical CGM; improvements target enzyme stability, MARD reduction, and drift correction.
- Fluorescence-based implantables — Long-duration implantable sensors using fluorescent chemistries provide extended runtime (months) and reduce user handling gminsights - U.S. Continuous Glucose Monitoring Market Report, 2025.
- Optical and spectroscopic non-invasive methods (Raman, photoacoustic, mid-IR) — High research intensity; successful clinical translation would remove insertion trauma and shift consumer adoption dynamics HME Square.
- Electrochemical Impedance Spectroscopy (EIS) and signal fusion — Used to reduce calibration burden and correct for tissue/sensor artifacts; critical for calibration-free ambitions.
- AI/ML predictive engines and decision support — Models that forecast glycemic trends and deliver prescriptive cues (exercise, insulin adjustments, carbohydrate intake) are evolving into reimbursable digital therapeutics when paired with clinician oversight OneTwenty, Inc..
- Multi-analyte sensor arrays — Platforms combining glucose with ketones, lactate, or other metabolites aim to broaden clinical signals and support more nuanced metabolic interventions.
Continuous Glucose Monitoring Funding
A total of 240 Continuous Glucose Monitoring companies have received funding.
Overall, Continuous Glucose Monitoring companies have raised $29.4B.
Companies within the Continuous Glucose Monitoring domain have secured capital from 1.2K funding rounds.
The chart shows the funding trendline of Continuous Glucose Monitoring companies over the last 5 years
Continuous Glucose Monitoring Companies
- Transdermal Diagnostics Ltd — Focuses on a 100% needle-free, wearable patch for continuous biomarker co-monitoring targeted at diabetes, prediabetes, and obesity populations. The company emphasizes pain-free sampling through transdermal transport techniques and couples the patch with an app-based analytics layer that supports consumer and clinician workflows. It has progressed through early clinical grants and seed venture funding that validate its non-invasive pathway
- NIQS Tech — A university spin-out developing quantum-enabled, truly non-invasive CGM sensors with a stated objective to remove needles and blood sampling from routine monitoring. Their work aims to produce continuous, accurate readings without interstitial insertion, positioning the company in the non-invasive technology cluster that targets higher adoption rates among needle-averse users
- BOYDSense — Developing breath-analysis biomarker devices with an initial diabetes focus; breath sampling offers low user burden and potentially low recurring costs. The company has advanced prototype validation and secured meaningful venture capital, indicating investor confidence in breath signatures as a complementary CGM pathway
- One Health Biosensing — Builds a micro-needle, intradermal multi-modal CGM designed for sustainable, low-cost daily wear. The platform targets cost-sensitive Type 2 patients and emphasizes reusable elements and reduced consumable waste to lower lifetime cost of ownership compared with current disposable-heavy models
- Apollon — A Seoul-based team leveraging Raman spectroscopy to deliver needle-free glucose sensing in a compact wearable form factor. Their strategy combines physics-based sensing with cloud analytics to accelerate clinical validation and market entry where regulatory pathways favor non-invasive claims
Gain a better understanding of 924 companies that drive Continuous Glucose Monitoring, how mature and well-funded these companies are.
924 Continuous Glucose Monitoring Companies
Discover Continuous Glucose Monitoring Companies, their Funding, Manpower, Revenues, Stages, and much more
Continuous Glucose Monitoring Investors
Gain insights into 1.4K Continuous Glucose Monitoring investors and investment deals. TrendFeedr’s investors tool presents an overview of investment trends and activities, helping create better investment strategies and partnerships.
1.4K Continuous Glucose Monitoring Investors
Discover Continuous Glucose Monitoring Investors, Funding Rounds, Invested Amounts, and Funding Growth
Continuous Glucose Monitoring News
Gain a competitive advantage with access to 3.4K Continuous Glucose Monitoring articles with TrendFeedr's News feature. The tool offers an extensive database of articles covering recent trends and past events in Continuous Glucose Monitoring. This enables innovators and market leaders to make well-informed fact-based decisions.
3.4K Continuous Glucose Monitoring News Articles
Discover Latest Continuous Glucose Monitoring Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
The continuous glucose monitoring sector is maturing from sensor hardware to data-driven metabolic platforms. Near-term upside derives from expanded reimbursement, extended sensor life, and OTC channels that broaden the addressable population. Medium-term value hinges on two outcomes: clinical validation and regulatory clearance of non-invasive sensing modalities, and the operationalization of predictive analytics into reimbursable interventions or closed-loop therapeutics. For commercial strategists, the immediate priorities are acquiring or partnering for non-invasive IP, building credible clinical evidence that meets regulator and payer expectations, and designing pricing/subscription models that align lifetime cost to demonstrated outcome improvements. Success will favor actors who integrate accurate sensing, reliable predictive software, and distribution strategies that reduce per-patient cost while preserving clinical fidelity.
We seek partnerships with industry experts to deliver actionable insights into trends and tech. Interested? Let us know!
